Definium Therapeutics reported Q3 2026 results, highlighting pivotal study progress and commercial development activity, but the statement provided few financia

Definium Therapeutics reported Q3 2026 results, highlighting pivotal study progress and commercial development activity, but the statement provided few financial specifics. The update follows three positive Phase 3 topline readouts for DT120 in depression and anxiety.